Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1407966-77-1

Post Buying Request

1407966-77-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 3-{1-[(3R)-1-Acryloyl-3-piperidinyl]-4-amino-1H-pyrazolo[3,4-d]py rimidin-3-yl}-N-(4-isopropyl-3-methylphenyl)benzamide

    Cas No: 1407966-77-1

  • No Data

  • No Data

  • No Data

  • Chemlyte Solutions
  • Contact Supplier

1407966-77-1 Usage

Chemical Properties

Beige Solid

Uses

Different sources of media describe the Uses of 1407966-77-1 differently. You can refer to the following data:
1. PF 06465469 is a covalent Inhibitors of Interleukin-2 Inducible T Cell Kinase (Itk) with nanomolar potency in a whole-blood assay.
2. (R)-3-[1-(1-Acryloylpiperidin-3-yl)-4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-(4-isopropyl-5-methylphenyl)benzamide is a potential covalent inhibitor of Interleukin-2 Inducible T Cell KInase (Itk). Itk is a member of the TEC-kinase family and is associated with the induction of T cell proliferation and drives cytokines through NFATc.

Check Digit Verification of cas no

The CAS Registry Mumber 1407966-77-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,0,7,9,6 and 6 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1407966-77:
(9*1)+(8*4)+(7*0)+(6*7)+(5*9)+(4*6)+(3*6)+(2*7)+(1*7)=191
191 % 10 = 1
So 1407966-77-1 is a valid CAS Registry Number.

1407966-77-1 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma

  • (PZ0209)  PF-06465469  ≥97% (HPLC)

  • 1407966-77-1

  • PZ0209-5MG

  • 1,020.24CNY

  • Detail
  • Sigma

  • (PZ0209)  PF-06465469  ≥97% (HPLC)

  • 1407966-77-1

  • PZ0209-25MG

  • 4,120.74CNY

  • Detail

1407966-77-1Downstream Products

1407966-77-1Relevant articles and documents

Covalent inhibitors of interleukin-2 inducible T cell kinase (ItK) with nanomolar potency in a whole-blood assay

Zapf, Christoph W.,Gerstenberger, Brian S.,Xing, Li,Limburg, David C.,Anderson, David R.,Caspers, Nicole,Han, Seungil,Aulabaugh, Ann,Kurumbail, Ravi,Shakya, Subarna,Li, Xin,Spaulding, Vikki,Czerwinski, Robert M.,Seth, Nilufer,Medley, Quintus G.

, p. 10047 - 10063 (2013/01/16)

We wish to report a strategy that targets interleukin-2inducible T cell kinase (Itk) with covalent inhibitors. Thus far, covalent inhibition of Itk has not been disclosed in the literature. Structure-based drug design was utilized to achieve low nanomolar potency of the disclosed series even at high ATP concentrations. Kinetic measurements confirmed an irreversible binding mode with off-rate half-lives exceeding 24 h and moderate on-rates. The analogues are highly potent in a cellular IP1 assay as well as in a human whole-blood (hWB) assay. Despite a half-life of approximately 2 h in resting primary T cells, the covalent inhibition of Itk resulted in functional silencing of the TCR pathway for more than 24 h. This prolonged effect indicates that covalent inhibition is a viable strategy to target the inactivation of Itk.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1407966-77-1